Table 1 Summary of studies describing the incidence of SNAEs in various patient populations

EuroSIDA

A prospective observational cohort of HIV-infected patients in Europe, Israel and Argentina followed from 2001-09.

12844

73

39

178

403

6

24

1.8

[14]

SMART (S) ESPRIT(E)

S: HIV-infected patients with CD4 count >350 cells/μL were randomized to either CD4 count guided episodic use of ART or to continuous use of ART. E: HIV-infected patients with CD4 count >300 cells/μL were randomized to interleukin-2 plus ART or to ART alone.

S: 5472 E: 4111

S: 2.4 E: 6.8

S: 73 E: 81

S: 43 E: 40

S: 250 E: 197

S: 597 E: 457

S: 2

S: 15

1

[11, 27, 127]

An observational cohort of HIV-infected patients with CD4 count >500 cells/μL in Spain from 1996-2011.

547

10

80

43

348

630

5

28

1.4

[17]

CoRIS

A prospective multicenter observational cohort of HIV-infected patients in Spain followed from 2004-2010.

5185

2.1

79

36

342

4

12

2.9

[16]

A retrospective study of HIV-infected patients receiving ART in Botswana (B) and Nashville, USA (US); from 2002 (B) and 2003 (US)-2007.

B: 650 US: 1129

B: 3 US: 1.5

B: 31 US: 74

B: 33 US: 40

B: 199 US: 243

B: 1 US: 1.2

[19]

LATINA

A retrospective study of HIV-infected patients in Latin America from 1997-2007.

6007

2.5

70

0.9

[18]

APROCO/COPILOTE

A prospective observational cohort of HIV-infected patients in France followed from 1997-2006.

1231

7.3

77

36

279

5

23

10.5

[20]

OPTIMA

HIV-infected patients with resistance to at least 2 different multidrug regimens were randomized to (a) re-treatment with either standard (≤4) or intensive (≥5) antiretroviral drugs and (b) either treatment starting immediately or after a 12-week monitored ART interruption.

368

4

98

48

107

11

22

61.0

[12]

ATHENA

An observational cohort of ART naive HIV-infected patients starting ART in the Netherlands, 1996-2010.

6440

3.9

75

39

200

7

6

1.2

[21]